Caris Life Sciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Irving, Texas. The company went IPO on 2025-06-18. Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The firm develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
Mr. David Halbert is the Chairman of the Board of Caris Life Sciences Inc, joining the firm since 2008.
What is the price performance of CAI stock?
The current price of CAI is $19.13, it has increased 0.02% in the last trading day.
What are the primary business themes or industries for Caris Life Sciences Inc?
Caris Life Sciences Inc belongs to Biotechnology industry and the sector is Health Care
What is Caris Life Sciences Inc market cap?
Caris Life Sciences Inc's current market cap is $5.4B
Is Caris Life Sciences Inc a buy, sell, or hold?
According to wall street analysts, 12 analysts have made analyst ratings for Caris Life Sciences Inc, including 6 strong buy, 6 buy, 1 hold, 0 sell, and 6 strong sell